A diverse coalition of scientists, advocates, and healthcare leaders working to advance access to life-saving monoclonal antibody therapies.
We champion the innovation, development, and equitable access to monoclonal antibody therapies that can save lives and reduce the burden of infectious disease.
The Antibody Innovation Alliance brings together diverse voices from across the biomedical ecosystem — from cutting-edge research labs to patient advocacy groups, from healthcare providers to policy makers.
Our shared belief: that mAbs represent a transformative advance in infectious disease prevention and treatment, one that deserves broader awareness, understanding, and support.
We work to ensure that this powerful tool reaches the people who need it most, when they need it most.
Supporting continued research and development to advance mAb technology, improve efficacy, and expand therapeutic applications across more diseases.
Advocating for policies and systems that ensure equitable access to mAb therapies regardless of geography, socioeconomic status, or insurance coverage.
Raising awareness about mAb science, safety, and efficacy among patients, providers, and policymakers to drive informed decision-making.
Leading developers of next-generation antibody therapies.
Academic and medical centers advancing antibody science.
Organizations representing communities most in need.
Clinicians on the front lines of patient care.